|
Basic Characteristics of Mutations
|
|
Mutation Site
|
V207I |
|
Mutation Site Sentence
|
Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
RT |
|
Standardized Encoding Gene
|
P
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Hepatitis B Virus Infection
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
Lamivudine(LAM) |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
15872296
|
|
Title
|
Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy
|
|
Author
|
Zollner B,Sterneck M,Wursthorn K,Petersen J,Schroter M,Laufs R,Feucht HH
|
|
Journal
|
Journal of clinical microbiology
|
|
Journal Info
|
2005 May;43(5):2503-5
|
|
Abstract
|
The reverse transcriptase V207I mutation within the hepatitis B virus (HBV) polymerase is associated with resistance to lamivudine in vitro. The prevalence of this mutation in treatment-naive patients was 1% (1/96). A follow-up of the patient carrying this mutation prior to treatment revealed no loss of sensitivity of HBV to lamivudine in vivo.
|
|
Sequence Data
|
-
|